Delix Therapeutics
Clinical-stage biotechnology company developing non-hallucinogenic neuroplasticity-promoting therapeutics for psychiatric and neurological disorders based on psychedelic compound research.
Notes
Delix Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, developing a novel class of neuroplasticity-promoting therapeutics derived from research on psychedelic compounds. The company's approach involves creating non-hallucinogenic versions of psychedelic molecules that retain their therapeutic potential for treating psychiatric and neurological conditions.
The company was founded based on pioneering research from UC Davis showing that psychedelics promote neuroplasticity, and that non-hallucinogenic analogs can be designed to provide therapeutic benefits without the hallucinogenic effects. Delix's compounds, called neuroplastogens, are designed to be administered in an outpatient setting without the need for extended supervision.
Team
- Mark Rus - Co-founder & CEO
- David Olson, Ph.D. - Co-founder & Chief Scientific Officer (UC Davis Professor)
- Peter Bergethon, M.D. - Chief Medical Officer
Additional Research Findings
- Founded in 2019
- Based on research from UC Davis
- Developing neuroplastogens - non-hallucinogenic compounds that promote neuroplasticity
- Lead program: DLX-001, a non-hallucinogenic neuroplastogen
- Target indications: depression, PTSD, and other psychiatric conditions
- Raised over $100 million in funding
- Investors include Pura Vida Investments, Mass General Brigham Ventures, RA Capital
- Spun out from UC Davis research
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| OMX Ventures | San Francisco, California, USA | biotech-focused | seedseries-a | 23 |